Trial Profile

An Open Label, Randomized, Three-Period Study in Healthy Subjects to Investigate the Effect of AZD5055 on the Pharmacokinetics of Nintedanib.

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 20 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 5055 (Primary) ; Nintedanib (Primary)
Indications Idiopathic pulmonary fibrosis
Focus Pharmacokinetics
Sponsors AstraZeneca

Most Recent Events

21 Sep 2023 Status changed from recruiting to discontinued.
20 Jun 2023 Planned End Date changed from 21 Sep 2023 to 30 Aug 2023.
20 Jun 2023 Planned primary completion date changed from 21 Sep 2023 to 30 Aug 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com